

BIO RAD LABORATORIES INC
 Form 4
 November 18, 2010

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL
 OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 TSINGOS CHRISTINE A

2. Issuer Name and Ticker or Trading Symbol
 BIO RAD LABORATORIES INC
 [BIO, BIO.B]

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

(Last) (First) (Middle)
 C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE

3. Date of Earliest Transaction (Month/Day/Year)
 11/18/2010

____ Director
 Officer (give title below)
 ____ 10% Owner
 ____ Other (specify below)
 CFO

(Street)
 HERCULES, CA 94547

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount or Price		
Bio-Rad A Common Stock	11/18/2010		M		5,000 A \$ 57.49	8,335.0979 (1)	D
Bio-Rad A Common Stock	11/18/2010		M		4,000 A \$ 62.47	12,335.0979	D
Bio-Rad A Common Stock	11/18/2010		S		9,000 D \$ 95.0291 (2)	3,335.0979	D

Edgar Filing: BIO RAD LABORATORIES INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares
Incentive Stock Option (right to buy)	\$ 57.49	11/18/2010		M	1,617	⁽³⁾ 02/09/2015	Bio-Rad A Common Stock	1,617
Non-Qualified Stock Option (right to buy)	\$ 57.49	11/18/2010		M	3,383	⁽³⁾ 02/09/2015	Bio-Rad A Common Stock	3,383
Incentive Stock Option (right to buy)	\$ 62.47	11/18/2010		M	680	⁽⁴⁾ 04/03/2016	Bio-Rad A Common Stock	680
Non-Qualified Stock Option (right to buy)	\$ 62.47	11/18/2010		M	3,320	⁽⁴⁾ 04/03/2016	Bio-Rad A Common Stock	3,320

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

TSINGOS CHRISTINE A
C/O BIO-RAD LABORATORIES, INC.
1000 ALFRED NOBEL DRIVE
HERCULES, CA 94547

CFO

Signatures

Christine A.
Tsingos

11/18/2010

__Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Includes 99.0544 shares acquired under the Bio-Rad Laboratories employee stock purchase plan on September 30, 2010.

(2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$94.96 to \$95.13. The reporting person undertakes to provide to Bio-Rad Laboratories, any security holder of Bio-Rad Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

(3) The stock option, granted on February 9, 2005, vested over five years at 20% per year on the yearly anniversary date of the grant.

(4) The stock option, granted on April 3, 2006, vests over five years at 20% per year on the yearly anniversary date of the grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.